A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China: Updated interim analysis from the NER-Tree study.
Xiaojia Wang(China Agricultural University), Jin Zhang(Shanghai Jiao Tong University), Jie Ma(Zhengzhou University), Anqin Zhang(Guangdong Province Women and Children Hospital), Jinhui Ye(The First People's Hospital of Zhaoqing), Xinhong Wu(Hubei Cancer Hospital), Yuanqi Zhang(Guangdong Medical College), Xinlan Liu(Yunnan Agricultural University), Haiguang Liu(Arizona State University), Guoqin Jiang(Soochow University), Yongsheng Wang(Shandong Tumor Hospital), Shihui Ma(Tianjin University of Technology), Suisheng Yang, Yiding Chen(Second Affiliated Hospital of Zhejiang University), Quchang Ouyang(Hunan Cancer Hospital), Fuguo Tian(Shanxi Provincial Cancer Hospital), Jianxia Liu(Minzu University of China), Jidong Gao(Chinese Academy of Medical Sciences & Peking Union Medical College), Shuqun Zhang(Second Affiliated Hospital of Xi'an Jiaotong University), Jundong Wu(Shantou University)
Cited by 0
Related Papers
Lipidic cubic phase injector facilitates membrane protein serial femtosecond crystallography
|Nature Communications|2014|596
Durable Complete Response After Discontinuation of Pembrolizumab in Patients With Metastatic Melanoma
|Journal of Clinical Oncology|2017|485
Serial time-resolved crystallography of photosystem II using a femtosecond X-ray laser
|Nature|2014|470
Baseline Tumor Size Is an Independent Prognostic Factor for Overall Survival in Patients with Melanoma Treated with Pembrolizumab
|Clinical Cancer Research|2018|311